NCAPD3

Across TCGA pan-cancer cohorts, NCAPD3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NCAPD3 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher NCAPD3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NCAPD3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where NCAPD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.928	0.563	<.001	30	view →
PDAC	OS	Median	IV	0.194	0.956	.038	9	view →
LUAD	DFS	Quartile	II,III,IV	0.920	0.618	.028	5	view →
OV	DFS	Median	All	0.874	1.000	.043	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NCAPD3–LSCC (OS)

Open the LSCC breakdown →